Nicholas Ching Hai Wu, PhD

The findings provide direction for future vaccines or therapies that may offer broader protection against variants.

The compound hits a vulnerable spot on multiple strains of the flu, attacking the virus in a whole new way.

Findings of the new study support many vaccine strategies currently being used to tackle the new coronavirus.

Some common strains of influenza are able to mutate to evade some of the broad-acting antibodies that could be elicited by a universal flu vaccine. 

Even though the coronaviruses that cause SARS and COVID-19 are closely related and infect cells the same way, they aren’t cross-protective in cell culture experiments.

An antibody recovered from a survivor of the SARS epidemic in the early 2000s has revealed a potential vulnerability of the coronavirus at the root of COVID-19.

Preparing a seasonal flu vaccine with the G186V mutation may prevent a vexing problem that commonly occurs during the vaccine manufacturing process.

The new study shows exactly why egg-based manufacturing is a problem for the H3N2 influenza subtype.